US FDA suggests increased testing of devices affected by Japan earthquake
This article was originally published in SRA
The US Food and Drug Administration has sent a letter to all foreign and domestic medical device establishments affected by Japan's March earthquake and tsunami, asking them to carry out increased sampling and testing of incoming raw materials and components as well as of finished diagnostic and other medical devices prior to product release1.
You may also be interested in...
Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Sixty-nine guidance documents have been posted on the tracker since its last update.
A UK regulator with the MHRA is concerned that bioanalytical laboratories are not being given enough time to do their job properly by drug companies under pressure to ensure their clinical trials remain on schedule.
The UK regulator is expecting a rise in amendments and deviations to ongoing clinical investigations of medical devices due to the COVID-19 pandemic and has issued advice on how companies should manage these.